Swamy Yeleswaram

4.1k total citations
65 papers, 1.7k citations indexed

About

Swamy Yeleswaram is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Swamy Yeleswaram has authored 65 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Hematology, 21 papers in Genetics and 19 papers in Oncology. Recurrent topics in Swamy Yeleswaram's work include Myeloproliferative Neoplasms: Diagnosis and Treatment (15 papers), Chronic Myeloid Leukemia Treatments (15 papers) and Dermatology and Skin Diseases (7 papers). Swamy Yeleswaram is often cited by papers focused on Myeloproliferative Neoplasms: Diagnosis and Treatment (15 papers), Chronic Myeloid Leukemia Treatments (15 papers) and Dermatology and Skin Diseases (7 papers). Swamy Yeleswaram collaborates with scholars based in United States, Canada and Netherlands. Swamy Yeleswaram's co-authors include William V. Williams, Naresh Punwani, Jack Shi, Peggy Scherle, Xuejun Chen, Thomas Emm, Yvonne Lo, Sharon Diamond, Ryan McGee and Jason Boer and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Nature Reviews Drug Discovery.

In The Last Decade

Swamy Yeleswaram

61 papers receiving 1.7k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Swamy Yeleswaram United States 21 461 447 433 394 369 65 1.7k
Mohamed‐Eslam F. Mohamed United States 24 172 0.4× 450 1.0× 222 0.5× 465 1.2× 444 1.2× 64 2.1k
Roxanne C. Jewell United States 22 608 1.3× 1.1k 2.5× 259 0.6× 251 0.6× 270 0.7× 59 1.8k
Ke Lin United Kingdom 27 927 2.0× 476 1.1× 868 2.0× 210 0.5× 702 1.9× 72 2.4k
Ken Ohmine Japan 21 605 1.3× 528 1.2× 210 0.5× 368 0.9× 119 0.3× 82 1.4k
Annemieke Kuil Netherlands 19 617 1.3× 1.4k 3.1× 565 1.3× 216 0.5× 322 0.9× 23 2.4k
Eunju Hurh United States 20 990 2.1× 210 0.5× 210 0.5× 89 0.2× 171 0.5× 43 2.2k
Juthamas Sukbuntherng United States 24 541 1.2× 490 1.1× 1.3k 3.0× 499 1.3× 414 1.1× 54 2.2k
Alain Thibault United States 24 1.2k 2.6× 694 1.6× 286 0.7× 560 1.4× 133 0.4× 49 2.5k
Alice A. Gibson United States 23 391 0.8× 790 1.8× 101 0.2× 140 0.4× 45 0.1× 46 1.4k
Toshiyuki Kitano Japan 18 782 1.7× 536 1.2× 86 0.2× 139 0.4× 234 0.6× 70 1.6k

Countries citing papers authored by Swamy Yeleswaram

Since Specialization
Citations

This map shows the geographic impact of Swamy Yeleswaram's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Swamy Yeleswaram with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Swamy Yeleswaram more than expected).

Fields of papers citing papers by Swamy Yeleswaram

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Swamy Yeleswaram. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Swamy Yeleswaram. The network helps show where Swamy Yeleswaram may publish in the future.

Co-authorship network of co-authors of Swamy Yeleswaram

This figure shows the co-authorship network connecting the top 25 collaborators of Swamy Yeleswaram. A scholar is included among the top collaborators of Swamy Yeleswaram based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Swamy Yeleswaram. Swamy Yeleswaram is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Chen, Xuejun, et al.. (2023). Itacitinib Population Pharmacokinetics and Exposure‐Response in Patients With Acute Graft‐Versus‐Host Disease. The Journal of Clinical Pharmacology. 63(5). 622–632.
2.
Wang, Anlai, Ke Zhang, Joshua R. Hummel, et al.. (2022). Discovery of Pyrazolopyridine Derivatives as HPK1 Inhibitors. ACS Medicinal Chemistry Letters. 14(1). 5–10. 8 indexed citations
3.
Ji, Tao, Kevin Rockich, Phillip Wang, et al.. (2021). Evaluation of drug-drug interactions of pemigatinib in healthy participants. European Journal of Clinical Pharmacology. 77(12). 1887–1897. 13 indexed citations
4.
Persaud, Indushekhar, et al.. (2020). Plasma pharmacokinetics and distribution of ruxolitinib into skin following oral and topical administration in minipigs. International Journal of Pharmaceutics. 590. 119889–119889. 15 indexed citations
5.
Kaul, Sanjeev, et al.. (2019). Abstract LB-268: Assessment of flat dosing strategy for INCMGA00012 in patients with advanced tumors. Cancer Research. 79(13_Supplement). LB–268. 2 indexed citations
6.
Barbour, April, Xuejun Chen, & Swamy Yeleswaram. (2019). Population Pharmacokinetic Analysis of Itacitinib, a Selective JAK-1 Inhibitor. Biology of Blood and Marrow Transplantation. 25(3). S254–S254. 3 indexed citations
7.
8.
Ruggeri, Bruce, Matthew C. Stubbs, Ashish Juvekar, et al.. (2017). Abstract 1234: The novel FGFR4-selective inhibitor INCB062079 is efficacious in models of hepatocellular carcinoma harboring FGF19 amplification. Cancer Research. 77(13_Supplement). 1234–1234. 6 indexed citations
9.
Shi, Jack, Kevin Bowman, Xuejun Chen, et al.. (2016). Population Pharmacokinetic and Pharmacodynamic Modeling of Epacadostat in Patients With Advanced Solid Malignancies. The Journal of Clinical Pharmacology. 57(6). 720–729. 13 indexed citations
10.
Zhang, Yan, Mark S. Warren, Xuexiang Zhang, et al.. (2015). Impact on Creatinine Renal Clearance by the Interplay of Multiple Renal Transporters: A Case Study with INCB039110. Drug Metabolism and Disposition. 43(4). 485–489. 33 indexed citations
11.
Shi, Jack, Xuejun Chen, Fiona Lee, et al.. (2014). The pharmacokinetics, pharmacodynamics, and safety of baricitinib, an oral JAK 1/2 inhibitor, in healthy volunteers. The Journal of Clinical Pharmacology. 54(12). 1354–1361. 164 indexed citations
12.
Chen, Xuejun, Jack Shi, Thomas Emm, et al.. (2013). Pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in renal and hepatic impairment patients. Clinical Pharmacology in Drug Development. 3(1). 34–42. 27 indexed citations
13.
Punwani, Naresh, et al.. (2013). Evaluation of the effect of ruxolitinib on cardiac repolarization: A thorough QT study. Clinical Pharmacology in Drug Development. 3(3). 207–214. 8 indexed citations
14.
Shi, Jack, Xuejun Chen, Ryan McGee, et al.. (2011). The Pharmacokinetics, Pharmacodynamics, and Safety of Orally Dosed INCB018424 Phosphate in Healthy Volunteers. The Journal of Clinical Pharmacology. 51(12). 1644–1654. 123 indexed citations
15.
Fridman, Jordan S., Peggy Scherle, Robert J. Collins, et al.. (2011). Preclinical Evaluation of Local JAK1 and JAK2 Inhibition in Cutaneous Inflammation. Journal of Investigative Dermatology. 131(9). 1838–1844. 88 indexed citations
16.
Li, Yu, Thomas Emm, & Swamy Yeleswaram. (2011). Simultaneous determination of fluoxetine and its major active metabolite norfluoxetine in human plasma by LC‐MS/MS using supported liquid extraction. Biomedical Chromatography. 25(11). 1245–1251. 25 indexed citations
17.
Shi, Jack, Xuejun Chen, Thomas Emm, et al.. (2011). The Effect of CYP3A4 Inhibition or Induction on the Pharmacokinetics and Pharmacodynamics of Orally Administered Ruxolitinib (INCB018424 Phosphate) in Healthy Volunteers. The Journal of Clinical Pharmacology. 52(6). 809–818. 86 indexed citations
18.
Hu, Zilun, Charles F. Albright, Nilsa Graciani, et al.. (2010). Discovery of matrix metalloproteases selective and activated peptide–doxorubicin prodrugs as anti-tumor agents. Bioorganic & Medicinal Chemistry Letters. 20(3). 853–856. 12 indexed citations
19.
Shilling, Adam D., Frank M. Nedza, Thomas Emm, et al.. (2010). Metabolism, Excretion, and Pharmacokinetics of [14C]INCB018424, a Selective Janus Tyrosine Kinase 1/2 Inhibitor, in Humans. Drug Metabolism and Disposition. 38(11). 2023–2031. 86 indexed citations
20.
Burns, David, Chunhong He, Yanlong Li, et al.. (2007). Conversion of an MMP-potent scaffold to an MMP-selective HER-2 sheddase inhibitor via scaffold hybridization and subtle P1′ permutations. Bioorganic & Medicinal Chemistry Letters. 18(2). 560–564. 13 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Mohamed‐Eslam F. Mohamed Breakdown of academic impact, for papers by Roxanne C. Jewell Breakdown of academic impact, for papers by Ke Lin Breakdown of academic impact, for papers by Ken Ohmine Breakdown of academic impact, for papers by Annemieke Kuil Breakdown of academic impact, for papers by Eunju Hurh Breakdown of academic impact, for papers by Juthamas Sukbuntherng Breakdown of academic impact, for papers by Alain Thibault Breakdown of academic impact, for papers by Alice A. Gibson Breakdown of academic impact, for papers by Toshiyuki Kitano
Rankless by CCL
2026